{"id":"NCT00241644","sponsor":"GlaxoSmithKline","briefTitle":"Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants","officialTitle":"Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2005-10-19","resultsPosted":"2009-08-04","lastUpdate":"2016-12-09"},"enrollment":2089,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Rotavirus"],"interventions":[{"type":"BIOLOGICAL","name":"Rotarix™","otherNames":["GSK Biologicals' HRV vaccine"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rotarix 3-Dose Group","type":"EXPERIMENTAL"},{"label":"Rotarix 2-Dose Group","type":"EXPERIMENTAL"},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to determine if the GSK Biologicals' human rotavirus (HRV) vaccine (pooled HRV groups) given concomitantly with routine expanded program on immunisation (EPI) vaccinations can prevent severe rotavirus gastroenteritis (≥11 on the 20-point Vesikari scoring system \\[Ruuska, 1990\\]) caused by the circulating wild-type RV strains during the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 5.\n\nThe primary objective will be reached if the lower limit of the 95% confidence interval (CI) on vaccine efficacy is \\>0%.\n\nThe Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","primaryOutcome":{"measure":"Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age","effectByArm":[{"arm":"Rotarix 2-dose Group","deltaMin":30,"sd":null},{"arm":"Rotarix 3-dose Group","deltaMin":26,"sd":null},{"arm":"Rotarix Pooled Group","deltaMin":56,"sd":null},{"arm":"Placebo Group","deltaMin":70,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":13,"countries":["Malawi","South Africa"]},"refs":{"pmids":["22520135","20107214","22520136","22520123","29564996","27895844","22974466"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":222,"n":1647},"commonTop":[]}}